Jiangsu Hengrui Medicine
600276.SS
#484
Rank
ยฃ33.77 B
Marketcap
ยฃ5.29
Share price
-3.83%
Change (1 day)
-0.57%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2024 (TTM): ยฃ0.64 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are ยฃ3.63 Billion. In 2023 the company made an earning of ยฃ0.52 Billion, an increase over its 2022 earnings that were of ยฃ0.47 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) ยฃ0.64 B23.44%
2023 ยฃ0.52 B11.4%
2022 ยฃ0.47 B-13.65%
2021 ยฃ0.54 B-34.21%
2020 ยฃ0.82 B15.95%
2019 ยฃ0.71 B33.03%
2018 ยฃ0.53 B20.89%
2017 ยฃ0.44 B23.89%
2016 ยฃ0.35 B11.21%
2015 ยฃ0.32 B39.5%
2014 ยฃ0.23 B20.61%
2013 ยฃ0.19 B11.46%
2012 ยฃ0.17 B29.7%
2011 ยฃ0.13 B31.16%
2010 ยฃ0.10 B27.92%
2009 ยฃ79.02 M5.8%
2008 ยฃ74.69 M79.95%
2007 ยฃ41.5 M32.89%
2006 ยฃ31.23 M38.19%
2005 ยฃ22.6 M21.56%
2004 ยฃ18.59 M13.95%
2003 ยฃ16.31 M38.06%
2002 ยฃ11.82 M